Shares Magazine
0.55p+0.00 (+0.00%)04 Aug 2025, 16:16
Jump to:
Verici Dx PLC Fundamentals
| Company Name | Verici Dx PLC | Last Updated | 2025-08-04 |
|---|---|---|---|
| Industry | Diagnostics & Research | Sector | Healthcare |
| Shares in Issue | 1.426 bn | Market Cap | £7.84 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -$0.03 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0495 | Debt Equity Ratio | 0.0359 |
| Asset Equity Ratio | 1.4230 | Cash Equity Ratio | 0.7713 |
| Quick Ratio | 2.0172 | Current Ratio | 2.24 |
| Price To Book Value | 1.9670 | ROCE | 0 |
Verici Dx PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Verici Dx PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $858,000.00 | $1.36 m | $2.01 m |
| Intangible Assets | $2.07 m | $2.09 m | $1.97 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $2.93 m | $3.45 m | $3.98 m |
| Stocks | 0 | 0 | 0 |
| Debtors | $50,000.00 | $1.10 m | $177,000.00 |
| Cash & Equivalents | $4.06 m | $2.65 m | $9.80 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $7.49 m | $7.44 m | $14.30 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $2.04 m | $3.51 m | $2.25 m |
| Creditors after 1 year | $189,000.00 | $377,000.00 | $544,000.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $2.23 m | $3.88 m | $2.80 m |
| Net assets | $5.26 m | $3.56 m | $11.51 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $310,000.00 | $219,000.00 | $219,000.00 |
| Share Premium | $40.37 m | $32.95 m | $32.95 m |
| Profit / Loss | -$5.87 m | -$8.73 m | -$11.41 m |
| Other Equity | $5.26 m | $3.56 m | $11.51 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | $5.26 m | $3.56 m | $11.51 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.03 | $0.10 | $0.05 |
| Debt-to-Equity | $0.04 | $0.11 | $0.05 |
| Assets / Equity | 1.4230 | 1.4230 | 1.4230 |
| Cash / Equity | 0.7713 | 0.7713 | 0.7713 |
| EPS | -$0.03 | -$0.05 | -$0.07 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | -$6.02 m | -$7.16 m | -$10.07 m |
| Cashflow before financing | $1.30 m | -$7.35 m | $2.61 m |
| Increase in Cash | $1.36 m | -$7.42 m | $1.30 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $3.34 m | $1.01 m | 0 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -$6.11 m | -$8.87 m | -$11.46 m |
| Pre-Tax profit | -$5.87 m | -$8.73 m | -$11.41 m |
Verici Dx PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients. |
| Latest Interim Date | 5 Aug 2025 |
| Latest Fiscal Year End Date | 30 Jun 2025 |
Verici Dx PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2025-07-24 | Mr. Julian Huw Baines MBE | Non-Executive Director,Chairman |
| 2025-07-24 | Sir Ian James Carruthers OBE | Non-Executive Director,Senior Independent Non-Executive Director |
| 2025-06-30 | Mr. James Renwick McCullough | Non-Executive Director |
| 2021-07-01 | Dr. Barbara Murphy | Non-Executive Director |
| 2025-07-24 | Ms. Sara Jane Barrington | Executive Director,Chief Executive Officer |
| 2025-06-30 | Dr. Lorenzo Giovanni Gallon | Non-Executive Director |
Verici Dx PLC Contact Details
| Company Name | Verici Dx PLC |
|---|---|
| Address | 19 Stanwell Road, Avon House, Cardiff, CF64 2EZ |
| Telephone | +44 2920710570 |
| Website | https://www.vericidx.com |
Verici Dx PLC Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Close Brothers Group PLC | 491.40 | 23.53 |
| Lloyds Banking Group PLC | 82.56 | 9.00 |
| Aston Martin Lagonda Global Holdings PLC | 71.60 | 6.79 |
| Watches Of Switzerland Group PLC | 346.20 | 5.94 |
| Ocado Group PLC | 349.10 | 5.56 |
| 4Imprint Group PLC | 3,735.00 | 5.21 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Auction Technology Group PLC | 376.00 | -21.67 |
| Senior PLC | 187.20 | -3.51 |
| Haleon PLC | 355.80 | -2.63 |
| Inchcape PLC | 672.00 | -2.04 |
| Rentokil Initial PLC | 354.30 | -2.02 |
| Pantheon Infrastructure PLC | 102.00 | -1.92 |